LXRXLexicon Pharmaceuticals, Inc.

SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.

In early August 2026, Lexicon Pharmaceuticals reported second-quarter results showing revenue of US$692,000 versus US$28.87 million a year earlier, alongside a shift from net income of US$3.25 million to a net loss of US$31.78 million and wider per-share losses. On the same day, the company filed two shelf registrations totaling about US$44.73 million in common stock capacity, highlighting both the strain on its current financial position and its intention to preserve flexibility for future...

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) is back in focus after reporting completion of patient randomization in its global Phase 3 SONATA HCM trial of sotagliflozin in hypertrophic cardiomyopathy, with enrollment beyond the original target. See our latest analysis for Lexicon Pharmaceuticals. Against this backdrop, Lexicon Pharmaceuticals’ share price sits at US$2.32, with a 90 day share price return of 44.10% and year to date share price return of 103.51%. The 1 year total shareholder return of...